Szymon Macioszek
Overview
Explore the profile of Szymon Macioszek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wawrzyniak R, Gresner P, Lewicka E, Macioszek S, Furga A, Zieba B, et al.
J Proteome Res
. 2023 Oct;
23(8):2795-2804.
PMID: 37827514
Pulmonary arterial hypertension (PAH) is a severe, multifactorial, and frequently misdiagnosed disorder. The aim of this observational study was to compare the plasma and urine metabolomic profiles of PAH patients...
2.
Rajska A, Buszewska-Forajta M, Macioszek S, Wawrzyniak R, Wityk P, Berg A, et al.
J Pharm Biomed Anal
. 2023 Aug;
235:115602.
PMID: 37536113
Despite a large number of studies, the pathogenesis of polycystic ovary syndrome (PCOS) still remains unexplained. In light of ambiguous observations reported in metabolomics, there is a need to carry...
3.
Macioszek S, Dudzik D, Biesemans M, Wozniak A, Schoffski P, J Markuszewski M
Analyst
. 2023 Jul;
148(16):3883-3891.
PMID: 37458061
Metabolites in biological matrices belong to diverse chemical groups, ranging from non-polar long-chain fatty acids to small polar molecules. The goal of untargeted metabolomic analysis is to measure the highest...
4.
Macioszek S, Dudzik D, Bartoszewski R, Stokowy T, Lambrechts D, Boeckx B, et al.
Transl Oncol
. 2023 Feb;
30:101632.
PMID: 36774883
Background: Although imatinib is a well-established first-line drug for treating a vast majority of gastrointestinal stromal tumours (GIST), GISTs acquire secondary resistance during therapy. Multi-omics approaches provide an integrated perspective...
5.
Macioszek S, Dudzik D, Jacyna J, Wozniak A, Schoffski P, J Markuszewski M
Metabolites
. 2021 Aug;
11(8).
PMID: 34436495
Gastrointestinal stromal tumour has already been well explored at the genome level; however, little is known about metabolic processes occurring in the sarcoma. Sample preparation is a crucial step in...
6.
Macioszek S, Wawrzyniak R, Kranz A, Kordalewska M, Struck-Lewicka W, Dudzik D, et al.
Front Mol Biosci
. 2021 Aug;
8:665661.
PMID: 34395519
Renal dysplasia is a severe congenital abnormality of the kidney parenchyma, which is an important cause of end-stage renal failure in childhood and early adulthood. The diagnosis of renal dysplasia...
7.
Kordalewska M, Macioszek S, Wawrzyniak R, Sikorska-Wisniewska M, Sledzinski T, Chmielewski M, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2019 Apr;
1117:49-57.
PMID: 30999273
Changes in metabolites composition can reflect currently present pathological processes in a living organism and constitute a basis for diagnosis and treatment improvements. Thus, the multiplatform metabolomics approach was applied...
8.
Grochocki W, Buszewska-Forajta M, Macioszek S, J Markuszewski M
Molecules
. 2019 Mar;
24(6).
PMID: 30909656
Urinary pterins have been found as potential biomarkers in many pathophysiological conditions including inflammation, viral infections, and cancer. However, pterins determination in biological samples is difficult due to their degradation...
9.
Wawrzyniak R, Kosnowska A, Macioszek S, Bartoszewski R, Jan Markuszewski M
Sci Rep
. 2018 Jun;
8(1):9541.
PMID: 29934622
Plasma untargeted metabolomics is a common method for evaluation of the mechanisms underlying human pathologies and identification of novel biomarkers. The plasma proteins provide the environment for transport of hydrophobic...